A Phase I Study of Oral MEK162 in Japanese Patients With Advanced Solid Tumors
Status:
Completed
Trial end date:
2018-02-01
Target enrollment:
Participant gender:
Summary
In this study, MEK162 will be administered to Japanese patients with advanced solid tumors
whose disease has progressed despite standard therapy or for whom no standard therapy exists.
The trial will investigate the safety and tolerability and determine the MTD of MEK162 in
Japanese patients.
Phase:
Phase 1
Details
Lead Sponsor:
Array BioPharma Array Biopharma, now a wholly owned subsidiary of Pfizer